Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ritu Saini

MOHS-Micrographic Surgery Rockaway Park, NY Medical Doctor

NPI 1477763977 CMS profile 66449

11412 Beach Channel Dr, Ste 5, Rockaway Park, NY 11694

Open in the dashboard

General payments

$4,653

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ritu Saini of Rockaway Park, NY is reported in the CMS Open Payments database as having received $4,653 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,015 21
2024 General $513 16
2023 General $795 33
2022 General $688 29
2021 General $750 31
2020 General $479 23
2019 General $413 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ritu Saini
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Ritu Saini were reported at $1,015. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Ritu Saini MOHS-Micrographic Surgery median Middle half National median
2019 $413 $316 $106–$785 $163
2020 $479 $162 $68–$412 $114
2021 $750 $243 $87–$654 $132
2022 $688 $300 $102–$887 $149
2023 $795 $364 $125–$1,010 $160
2024 $513 $445 $142–$1,108 $164
2025 $1,015 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $716 35 payments
  2. Sun Pharmaceutical Industries Inc. $529 24 payments
  3. Galderma Laboratories, L.P. $456 9 payments
  4. Genzyme Corporation $410 11 payments
  5. Lilly USA, LLC $362 11 payments
  6. Janssen Biotech, Inc. $361 12 payments
  7. Amgen Inc. $360 12 payments
  8. E.R. Squibb & Sons, L.L.C. $192 4 payments
  9. Regeneron Healthcare Solutions, Inc. $173 7 payments
  10. Incyte Corporation $137 6 payments
  11. Other $958 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,573 174 payments
  2. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $651 32 payments
  2. DUPIXENT $410 11 payments
  3. Otezla $360 12 payments
  4. ILUMYA $321 15 payments
  5. NEMLUVIO $319 2 payments
  6. TREMFYA $240 7 payments
  7. SOTYKTU $192 4 payments
  8. HUMIRA $189 9 payments
  9. Winlevi $185 8 payments
  10. TALTZ $183 8 payments
  11. Other $2,170 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

920

Median for Dermatology: 534

Drug cost

$211,121

Median for Dermatology: $67,151

Branded share of claims

2.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Adapalene Generic 21 $97,006
Opzelura Ruxolitinib Phosphate Brand 15 $30,422
Acyclovir Generic 11 $16,564
Triamcinolone Acetonide Generic 135 $11,490
Amcinonide Generic 11 $11,332
Oxiconazole Nitrate Generic 19 $10,088
Hydrocortisone Generic 56 $4,386
Doxycycline Hyclate Generic 57 $3,884
Tretinoin Generic 40 $3,507
Ketoconazole Generic 133 $3,466

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$733,022

Of which drugs: $33,759

Medicare patients

498

Average age 76

Services billed

17,805

276 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 45%
Ischemic heart disease 35%
Depression 30%
COPD 21%
Alzheimer's or dementia 21%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 34 10,200 $13,165
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 42 86 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $131
$131 — —
TREMFYA
  • Janssen Biotech, Inc. $114
$114 — —
Otezla
  • Amgen Inc. $31
$31 — —
SKYRIZI
  • AbbVie, Inc. $26
$26 — —
VTAMA
  • Dermavant Sciences, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record